STAT News reports: Seeking to blunt concerns about access to its remdesivir treatment for Covid-19, Gilead Sciences (GILD) signed deals with five generic companies in India and Pakistan to manufacture and distribute the experimental medicine to 127 countries. Under the agreements, the companies can set their own prices, but will not have to pay royalties to Gilead until the World …
Read More »